EBS vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Compare Another Pair
Related Comparisons
EBS vs JNJ: Head-to-Head Comparison
This page compares Emergent BioSolutions Inc. (EBS) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.